ARCI

Alberta Research Chemicals Inc. (ARCI) is a Canadian biotechnology company and contract research organization (CRO) based in Edmonton, Alberta. The company specializes in knowledge-based drug discovery, offering services in organic synthesis, medicinal chemistry, and process development to the global pharmaceutical industry. Beyond its CRO services, ARCI maintains an internal pipeline focused on the development of novel small molecule therapeutics for oncology and infectious diseases. A key area of innovation for the company is the development of Toll-Like Receptor (TLR) ligands as next-generation vaccine adjuvants designed to induce robust and long-lasting immune responses. ARCI operates state-of-the-art research facilities and seeks to partner or out-license its proprietary therapeutic candidates and discovery platforms.